Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial

The optimal adjuvant endocrine therapy for HR-positive/HER2-positive breast cancer patients is unknown. We included in this analysis 784 patients with HR-positive/HER2-positive BC from the randomized ShortHER trial of adjuvant trastuzumab (1 year vs 9 weeks) + chemotherapy. At a median follow-up of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dieci, Maria Vittoria, Bisagni, Giancarlo, Bartolini, Stefania, Frassoldati, Antonio, Vicini, Roberto, Balduzzi, Sara, D’amico, Roberto, Conte, Pierfranco, Guarneri, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899279/
https://www.ncbi.nlm.nih.gov/pubmed/36739285
http://dx.doi.org/10.1038/s41523-023-00509-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899279/
https://www.ncbi.nlm.nih.gov/pubmed/36739285
http://dx.doi.org/10.1038/s41523-023-00509-2

Ejemplares similares